Table 2.
Injection Use by Number of Reported Industry Paymentsa
| No. of Reported Industry Payments | Mean (SD) | Injections by Category, % | ||||
|---|---|---|---|---|---|---|
| Total Injections | Aflibercept and Ranibizumab Injections | Bevacizumab Injections | Mean Aflibercept and Ranibizumab | Mean Bevacizumab | SD | |
| 0 (n = 1867) | 583.07 (690.54) | 242.75 (455.00) | 340.33 (425.54) | 29.6 | 70.4 | 33.6 |
| 1 (n = 434) | 786.21 (758.76) | 404.56 (573.50) | 381.64 (431.75) | 42.0 | 58.0 | 33.3 |
| 2 (n = 274) | 930.47 (789.83) | 517.42 (589.27) | 413.05 (444.66) | 50.6 | 49.4 | 32.7 |
| 3–5 (n = 278) | 1147.84 (852.14) | 727.74 (691.25) | 420.10 (482.96) | 58.0 | 42.0 | 31.5 |
| >5 (n = 158) | 1248.52 (840.37) | 923.91 (757.74) | 324.61 (330.22) | 67.6 | 32.4 | 28.5 |
| Correlation coefficient (95% CI)a | 0.24 (0.22 to 0.26) | 0.32 (0.29 to 0.34) | 0.07 (0.04 to 0.09) | 0.27 (0.25 to 0.29) | −0.27 (−0.25 to −0.29) | NA |
Abbreviation: NA, not applicable.
a
P < .001 for all comparisons. Correlation coefficients, 95% Cls, and significance calculations were derived using continuous variables.